Datasea Announces Entry into Agreements that Will Place its Acoustic High-Tech Products in a Total of 263 Beauty Stores in Northern China
The New Agreements Projected to Generate Sales of up to 140,000 Units and $11 Million in Revenue by Year End 2025 BEIJING, Jan. 6, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS, "Datasea" or "the Company"), a Nevada-based digital technology company specializing in acoustic high-tech and 5G AI multimodal digital innovation, today...
EMSRUN Medical Celebrates 15 Years of Excellence in Life-Saving Solutions
WUXI, China, Jan. 6, 2025 /PRNewswire/ -- EMSRUN Medical, a leader in tactical, pre-hospital, and civilian emergency medical solutions, marks its 15th anniversary this year. Since its establishment in 2010, the company has built an outstanding reputation for delivering critical solutions to combatants, first responders, and pre-hospital care providers. Entering this milestone year, EMSRUN continues to strengthen its commitment to...
Hanyang University, Korea’s Pioneer in Industry-Academia Collaboration, Debuts First Independent Pavilion at CES 2025
Featuring 13 groundbreaking innovations, including this year's Best of Innovation Award in Digital Health, to drive transformative solutions for societal change SEOUL, South Korea, Jan. 6, 2025 /PRNewswire/ -- Hanyang University, a global leader in industry-academia collaboration, is proud to announce its first independent pavilion at CES 2025 Eureka Park, further solidifying its position as a pioneer in innovation and...
Technoderma Medicines Completes Positive Ph2a Proof- of Concept Trial with Topical TDM-180935 Ointment for Atopic Dermatitis
CHENGDU, China, Jan. 6, 2025 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ointment in patients with Atopic Dermatitis (AD). This clinical trial in the AD program included 8 weeks dosing of two different active formulation strengths and...
Concord Medical Announces Result of 2024 Annual General Meeting
BEIJING, Jan. 6, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it held its 2024 annual general meeting of shareholders on December 27, 2024. At the meeting, the shareholders resolved by special resolution that amended and replaced...
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization The Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose...
Asieris and CDC Sign Investigational Product Supply Agreement for APL-1202 in Free-Living Amoeba Infections Treatment under Expanded Access Investigational New Drug Program
SHANGHAI, Jan. 6, 2025 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women's health with significant unmet medical needs, announced the signing of an investigational drug supply agreement under the Expanded Access Investigational New Drug (IND) Program with the Centers for Disease Control and Prevention (CDC)...
Spectricity Unveils S1-A Accessory Device for Plug-n-Play Spectral Imaging on Mobile Platforms
The S1-A Accessory Device will be revealed together with Spectricity's latest Skin Analysis demonstration at CES 2025, Westgate Hotel, Suite #12-121. MECHELEN, Belgium, Jan. 6, 2025 /PRNewswire/ -- Spectricity, a leading provider of multispectral imaging solutions for mobile devices, today announced the launch of its S1-A Accessory Device at CES 2025. Spectricity S1-A Accessory...
Docquity and HCDC Partner to Strengthen Preventive Medicine Education for Thousands of HCPs in Vietnam
Through this multi-year initiative, HCDC will tap on Docquity's digital capabilities and reach to arm over 3,000 HCPs across diverse fields with breakthroughs in preventive medicine HO CHI MINH, Vietnam, Jan. 6, 2025 /PRNewswire/ -- Docquity, Southeast Asia's largest community of healthcare professionals (HCPs), is working with the Ho Chi Minh City...
Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO and SUZHOU, China, Jan. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference. During the conference, Dr....
